| Jeffrey S Grand, Psyd, Pllc | |
|
101 Old York Rd Ste 202 Jenkintown PA 19046-3911 | |
| (215) 901-8791 | |
| Not Available |
| Full Name | Jeffrey S Grand, Psyd, Pllc |
|---|---|
| Speciality | Psychologist |
| Location | 101 Old York Rd Ste 202, Jenkintown, Pennsylvania |
| Authorized Official Name and Position | Jeffrey Grand (OWNER) |
| Authorized Official Contact | 2159018791 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey S Grand, Psyd, Pllc 1372 Warner Rd Jenkintown PA 19046-2536 Ph: (215) 901-8791 | Jeffrey S Grand, Psyd, Pllc 101 Old York Rd Ste 202 Jenkintown PA 19046-3911 Ph: (215) 901-8791 |
| NPI Number | 1346364957 |
|---|---|
| Provider Enumeration Date | 03/19/2007 |
| Last Update Date | 09/09/2021 |
| Certification Date | 09/09/2021 |
| Medicare PECOS PAC ID | 9234238023 |
|---|---|
| Medicare Enrollment ID | O20070619000686 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346364957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PS015842 (Pennsylvania) | Primary |
| Provider Name | Jeffrey Scott Grand |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1619953361 PECOS PAC ID: 1153350053 Enrollment ID: I20050811000074 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Anthony F Verdi |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1942489596 PECOS PAC ID: 8628007689 Enrollment ID: I20071127000584 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Kelli S Williams |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1205086188 PECOS PAC ID: 1355400771 Enrollment ID: I20081030000114 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Nicholas Stephen Patapis |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1831366186 PECOS PAC ID: 1052629169 Enrollment ID: I20151008002160 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Jeremy Schwarzbaum |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1295191294 PECOS PAC ID: 2163726613 Enrollment ID: I20160204000336 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Michael Edward Keesler |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1609228022 PECOS PAC ID: 7517246390 Enrollment ID: I20161118000656 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
| Provider Name | Jennie Brill Rodgers |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1518482058 PECOS PAC ID: 2466703236 Enrollment ID: I20180919000184 |
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
News Archive
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
"Because of Congress's inability to find answers to the ongoing Medicare physician payment dilemma, physicians across the country are unable to accept and treat new Medicare patients," Joseph W. Stubbs, MD, FACP, president of the American College of Physicians declared today as he considered the impending effects of the cut to the Sustainable Growth Rate.
However the latest research from the Children of the 90s project has shown no link between fish consumption and average birthweight once other factors have been taken into account. There was also no evidence of increased frequency of premature birth in mothers not eating fish.
› Verified 1 days ago
Mindful-well, Cdc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 261 Old York Rd Ste 709, Jenkintown, PA 19046 Phone: 215-917-5538 | |
Monroe Psychology, P.c. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 512 West Ave, Jenkintown, PA 19046 Phone: 215-885-1825 Fax: 215-885-8510 | |
Sunshine Healing & Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 328 Summit Ave Ste 120, Jenkintown, PA 19046 Phone: 215-360-3557 | |
Swift Integrated Wellness, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 207 Leedom St Ste 104, Jenkintown, PA 19046 Phone: 215-939-6113 | |
Embracing My Black Pen Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 Washington Ln Ste 304, Jenkintown, PA 19046 Phone: 267-809-5433 | |
Marsha J Friedman Phd Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 101 Greenwood Ave Ste 410, Jenkintown, PA 19046 Phone: 215-514-3464 | |
Gentle Force Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 610 York Rd Ste 400, Jenkintown, PA 19046 Phone: 267-704-9187 |